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http://dx.doi.org/1diseases (CTD). The objective of this study was to compare the risk of CTD diagnoses in
statin users and nonusers. This study was a propensity score-matched analysis of adult
patients (30 to 85 years old) in the San Antonio military medical community. The study was
divided into baseline (October 1, 2003 to September 30, 2005), and follow-up (October 1,
2005 to March 5, 2010) periods. Statin users received a statin prescription during ﬁscal year
2005. Nonusers did not receive a statin at any time during the study. The outcome measure
was the occurrence of 3 diagnosis codes of the International Classiﬁcation of Diseases, 9th
Revision, Clinical Modiﬁcation consistent with CTD. We described co-morbidities during
the baseline period using the Charlson Comorbidity Index. We created a propensity score
based on 41 variables. We then matched statin users and nonusers 1:1, using a caliper of
0.001. Of 46,488 patients who met study criteria (13,640 statin users and 32,848 nonusers),
we matched 6,956 pairs of statin users and nonusers. Matched groups were similar in terms
of patient age, gender, incidence of co-morbidities, total Charlson Comorbidity Index,
health care use, and medication use. The odds ratio for CTD was lower in statin users than
nonusers (odds ratio: 0.80; 95% conﬁdence interval: 0.64 to 0.99; p [ 0.05). Secondary
analysis and sensitivity analysis conﬁrmed these results. In conclusion, statin use was
associated with a lower risk of CTD. Published by Elsevier Inc. (Am J Cardiol
2013;112:883e888)Statins (hydroxyl-methyl-glutaryl-coenzyme A reductase
inhibitors) have been shown to interfere with downstream
signaling molecules that have been implicated in both pro-
inﬂammatory and anti-inﬂammatory processes.1 Speciﬁ-
cally, rheumatologic diseases are characterized by both
systemic inﬂammation and an increased risk of cardiovas-
cular disease,2 making these diseases an attractive area of
statin research. The effects of statins on the development of
connective tissue disease (CTD) have been debated. Some
studies have noted that statins may be protective against the
development of rheumatoid arthritis (RA),3,4 whereas others
did not observe a link between statin use and RA.5,6
Furthermore, a recent case-control study concluded that
statin use was associated with an increased risk of devel-
oping RA.7 The objective of this study was to examine they Department, San Antonio Uniformed Services Health
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0.1016/j.amjcard.2013.04.059association of statin therapy with CTD in a propensity score-
matched cohort of statin users and nonusers from a military
health care system, where patients have similar access and
standards of care.Methods
This study was approved by the Institutional Review Board
at the Brooke Army Medical Center. This is a retrospective
cohort analysis of patients who were enrolled as Tricare Prime
or Tricare Plus in the San Antonio area military health care
system. The database and study population have been
described elsewhere.8 Brieﬂy, the extracted data included
outpatient medical records, inpatient medical records, admin-
istrative data of services offered outside military facilities, and
pharmacy data. Outpatient medical records and inpatient
medical records contain all medical services activities, diag-
nosis codes, and procedure codes. Pharmacy data include
dispensed medications, regardless of the pharmacy location or
afﬁliation. TheManagement Analysis and Reporting Tool was
used to access and retrieve all patient encounter data and
prescription history regardless of encounters location or afﬁli-
ation. The utility and reliability of this tool in medical research
is well described in the literature.9e12
The study was divided into baseline period (October 1,
2003 to September 30, 2005), which was used to describe
baseline characteristics and follow-up period (October 1,
2005 to March 5, 2010), which was used to identify outcome
events. During the baseline period, we identiﬁed 2 patient
groups, statin users and nonusers. Statin users received
a statin prescription of at least 90-day supply during thewww.ajconline.org
Table 1
Baseline characteristics of statin users and nonusers in the unmatched cohort
Variable Users (n ¼ 13,640) Nonusers (n ¼ 32,848) p Value
Age (yrs), mean (SD) 60 (12) 45 (11) <0.0001
Male gender 7,957 (58.3%) 14,387 (43.8%) <0.0001
Co-morbid conditions
Acute myocardial infarction* 798 (5.9%) 121 (0.4%) <0.0001
Congestive heart failure* 747 (5.5) 164 (0.5%) <0.0001
Peripheral vascular disease* 859 (6.3%) 190 (0.6%) <0.0001
Cerebrovascular disease* 553 (4%) 226 (0.7%) <0.0001
Dementia* 58 (0.4%) 45 (0.1%) <0.0001
Chronic obstructive pulmonary diseases* 2,062 (15.1%) 2,462 (7.5%) <0.0001
Rheumatologic diseases* 290 (2.1%) 472 (1.4%) <0.0001
Peptic ulcer disease* 220 (1.6%) 264 (0.8%) <0.0001
Mild liver disease* 48 (0.4%) 116 (0.4) >0.99
Diabetes mellitus* 4,389 (32.2%) 859 (2.6%) <0.0001
Diabetes mellitus with complications* 1,664 (12.2%) 179 (0.5%) <0.0001
Hemiplegia/paraplegia 50 (0.4%) 27 (0.1%) <0.0001
Renal disease* 471 (3.5%) 117 (0.4%) <0.0001
Malignancy* 1,010 (7.4%) 1,102 (3.4%) <0.0001
Liver disease (moderate/severe)* 8 (0.1) 41 (0.1%) 0.06
Metastatic neoplasm* 48 (0.4%) 95 (0.3%) 0.3
HIV* 13 (0.1%) 39 (0.1%) 0.5
Illicit drug use 20 (0.1%) 65 (0.2%) 0.3
Alcohol abuse/dependence 133 (1%) 240 (0.7%) .008
Smoker 1,229 (9.0%) 1,911 (5.8%) <0.0001
Charlson Comorbidity Index score,* mean (SD) 1.2 (1.6) 0.3 (0.8) <0.0001
Health care utilization
Number of outpatient visits during baseline period, mean (SD) 41 (5) 23 (32) <0.0001
Number of admission during follow-up period, mean (SD) 0.4 (1.0) 0.2 (0.6) <0.0001
Number of outpatient visits during follow-up period, mean (SD) 119 (149) 64 (79) <0.0001
Number of admission during baseline period, mean (SD) 3 (3.1) 2 (2) <0.0001
Medications
Beta blocker 3,911 (28.7%) 2,167 (6.6%) <0.0001
Diuretic 5,121 (37.5%) 3,421 (10.4%) <0.0001
Calcium antagonist 3,516 (25.8%) 1,648 (5.0%) <0.0001
Nonstatin lipid-lowering drugs 2,324 (17.0%) 575 (1.8%) <0.0001
Angiotensin-receptor blockers/angiotensin converting enzyme inhibitors 7,988 (58.6%) 3,483 (10.6%) <0.0001
Oral hypoglycemic 2,821 (20.7%) 385 (1.2%) <0.0001
Cytochrome p450 1,466 (10.7%) 1,410 (4.3%) <0.0001
Aspirin 7,279 (53.4%) 2,667 (8.1%) <0.0001
Nonsteroidal anti-inﬂammatory drugs 7,572 (55.5%) 20,244 (61.6%) <0.0001
Selective serotonin reuptake inhibitors 2,514 (18.4%) 4,321 (13.2%) <0.0001
Systemic corticosteroid 532 (3.9%) 1,372 (4.2%) 0.08
Antipsychotic 180 (1.3%) 326 (1.0%) 0.001
Sedatives 2,864 (21.0%) 5,450 (16.6%) <0.0001
Tricyclic antidepressants 35 (0.3%) 58 (0.1%) 0.09
Mean HDL in baseline period (mg/dl)† 53 (15) 59 (18) <0.0001
Mean HDL in follow-up period (mg/dl)† 51 (14) 57 (17) <0.0001
Mean LDL in baseline period (mg/dl)† 105 (34) 111 (28) <0.0001
Mean LDL in follow-up period (mg/dl)† 98 (31) 112 (27) <0.0001
Cytochrome p 450: medications that inhibit the Cytochrome p450 system as identiﬁed in a recent Food and Drug Administration warning.18
HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol.
* Diagnosis is based on ICD-9-CM codes as identiﬁed in the Deyo method for applying the Charlson Comorbidity Index score.17
† Values for these laboratory measurements were missing in 8,647-7,520 patients in statin users and 26,546-18,619 patients in the nonusers.
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nonusers did not receive a statin at any time during the study.
Patients had to be 30 to 85 years of age, enrolled in
Tricare Prime or Tricare Plus in the San Antonio area
military health care system until the date of data extraction,
had to have 1 outpatient visit during the baseline period
and 1 outpatient visit during the follow-up period, and had
to receive 1 prescription medication during the baselineperiod. Hence, our cohort had complete data throughout the
study period.
We excluded burn and trauma patients; these patients were
identiﬁedbasedon the InternationalClassiﬁcationofDiseases,
9th Revision, Clinical Modiﬁcation (ICD-9-CM) codes. Codes
for burn patientswere those identiﬁedby theAgency forHealth
Research and Quality—Clinical Classiﬁcations Software
(AHRQ-CCS), category 24013; trauma codes were compiled
Table 2
Baseline characteristics of statin users and nonusers in the propensity score-matched cohort
Variable Users (n ¼ 6,956) Nonusers (n ¼ 6,956) p Value
Age (yrs), mean (SD) 57 (13) 57 (12) 0.2
Male gender 3,759 (54%) 3,816 (55%) 0.3
Co-morbid conditions
Acute myocardial infarction* 73 (1.0%) 68 (1.0%) 0.7
Congestive heart failure* 144 (2.1%) 124 (1.8%) 0.2
Peripheral vascular disease* 144 (2.1%) 134 (1.9%) 0.6
Cerebrovascular disease* 153 (2.2%) 148 (2.1%) 0.8
Dementia* 33 (0.5%) 28 (0.4%) 0.6
Chronic obstructive pulmonary disease* 836 (12.0%) 876 (12.6%) 0.3
Rheumatologic diseases* 158 (2.3%) 151 (2.2%) 0.7
Peptic ulcer disease* 97 (1.4%) 94 (1.4%) 0.8
Mild liver disease* 30 (0.4%) 31 (0.4%) 1
Diabetes mellitus* 697 (10.0%) 671 (9.6%) 0.5
Diabetes mellitus with complications* 198 (2.8%) 164 (2.4%) 0.08
Hemiplegia/paraplegia* 12 (0.2%) 8 (0.1%) 0.5
Renal disease* 96 (1.4%) 87 (1.3%) 0.6
Malignancy* 440 (6.3%) 439 (6.3%) 1
Liver disease (moderate/severe)* 4 (0.1%) 5 (0.1%) 1
Metastatic neoplasm* 24 (0.3%) 22 (0.3%) 0.9
HIV* 10 (0.1%) 8 (0.1%) 0.6
Alcohol abuse/dependence 66 (0.9) 71 (1) 0.7
Smoker 588 (8.5) 609 (8.8) 0.5
Illicit drug use 12 (0.2) 11 (0.2) 0.8
Charlson Comorbidity Score, mean (SD) 0.59 (1.1) 0.56 (1.3) 0.6
Health care utilization
Number of outpatient visits during baseline period, mean (SD) 32 (33) 32 (52) 0.6
Number of admission during baseline period, mean (SD) 0.3 (0.8) 0.3 (0.8) 0.2
Number of outpatient visits during follow-up period, mean (SD) 89 (83) 89 (124) 0.8
Number of admission during follow-up period, mean (SD) 0.8 (2) 0.8 (2) 0.4
Medications
Beta blocker 1,282 (18.4%) 1,279 (18.4%) 0.9
Diuretic 1,967 (28.3%) 1,942 (27.9%) 0.7
Calcium antagonist 1,141 (16.4%) 1,091 (15.7%) 0.2
Nonstatin lipid-lowering drugs 530 (7.6%) 495 (7.1%) 0.3
Angiotensin-receptor blockers/angiotensin converting enzyme inhibitors 2,420 (34.8%) 2,416 (34.7%) 1.0
Oral hypoglycemic 326 (4.7%) 292 (4.2%) 0.2
Cytochrome p450 447 (6.4%) 450 (6.5%) 0.9
Aspirin 2,207 (31.7%) 2,219 (30.5%) 0.1
Nonsteroidal anti-inﬂammatory drugs 3,998 (57.5%) 3,965 (57.0%) 0.6
Selective serotonin reuptake inhibitors 1,166 (16.8%) 1,135 (16.3%) 0.5
Systemic corticosteroid 275 (4.0%) 272 (3.9%) 0.9
Antipsychotic 95 (1.4%) 100 (1.4%) 0.7
Sedatives 1,375 (19.8%) 1,342 (19.3%) 0.5
Tricyclic antidepressants 16 (0.2%) 12 (0.2%) 0.5
Cytochrome p450: medications that inhibit the cytochrome p450 system as identiﬁed in a recent Food and Drug Administration warning.18
* Diagnosis is based on ICD-9-CM codes as identiﬁed in the Deyo method for applying the Charlson Comorbidity Index score.17
Miscellaneous/Statin and Connective Tissue Disease 885from ICD-9 manual and previous publications.14,15 We also
excluded patients who received a statin for <90 days or those
who started a statin after the baseline period to allow equal
follow-up periods in both patient groups.
The outcome measure was the occurrence of 3 separate
ICD-9-CM codes,16 during the follow-up period in either
the inpatient or outpatient setting, consistent with CTD as
identiﬁed by AHRQ-CCS categories 202, 210, and 211,
except for V-codes because they signify previous conditions
(Appendix A).13
We described patients’ co-morbidities using the Charlson
Comorbidity Index, Deyo et al method.17 A propensity score-matched cohort of statin users and nonusers was created using
41 variables (age, gender, 17 co-morbid conditions as listed in
Table 1 and identiﬁed from ICD-9-CM diagnoses of inpatient
or outpatients medical encounters, total Charlson Comorbidity
Index usingDeyomethod,17 health care utilization, and the use
of 14 medication groups as listed in Table 1).18
We performed the following analyses: primary analysis
in which we determined the risk of CTD in the propensity
score-matched cohort; secondary analysis in which we
determined the risk of CTD in relation to statin use in all
patients who met study criteria (unmatched cohort); and
sensitivity analysis in which we excluded patients with
Table 3
Prevalence of selected International Classiﬁcation of Diseases, 9th Revision, Clinical Modiﬁcation codes of connective tissue diseases in the propensity
score-matched group for statin users and nonusers
Selected ICD-9-CM Codes Diseases Identiﬁed by These Codes Users (n ¼ 6,956) Nonusers (n ¼ 6,956)
7140, 7142, 71430, 71431, 71432, 71433, 7144,
71481, 71489, 7149
Rheumatoid arthritis 104 (1.5%) 122 (1.8%)
7100 Systemic lupus erythematous 22 (0.3%) 34 (0.5%)
7103e7104 Dermatomyosotis and polymyositis 2 (0.03%) 9 (0.1%)
725 Polymyalgia rheumatica 33 (0.5%) 20 (0.3%)
7102 Sicca syndrome, keratoconjuctivitis sicca,
Sjogren’s disease
34 (0.5%) 40 (0.6%)
7109 Connective tissue disease (unspeciﬁed) 5 (0.1%) 19 (0.1%)
The selected ICD-9-CM codes are not necessarily comprehensive for their diagnoses but are more commonly utilized. Multiple diagnoses occurred
simultaneously in the same patients.
Table 4
Risk of outcome in statin users in comparison to nonusers in different cohorts
Variable Users Diagnosed With CTD Nonusers Diagnosed With CTD OR 95% CI p Value
Primary analysis
Risk of CTD in propensity score matched cohort 144 (2.1%) 179 (2.6%) 0.80 0.64 0.99 0.05
Secondary analysis
Risk of CTD in the unmatched cohort* 305 (2.2%) 532 (1.6%) 0.81* 0.65 0.99 0.05
Sensitivity analysis
Risk of CTD in propensity score incidence cohort 76 (1.1%) 106 (1.6%) 0.72 0.53 0.96 0.03
* Adjusted OR for age, gender, statin use, all comorbid conditions as in Table 1, total Charlson Comorbidity Index, number of outpatient medical encounters,
and inpatient admissions during each of the baseline period and the follow-up period, and use of different classes of medications as listed in Table 1.
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matched cohort and determined the risk of incidence of CTD
diagnosis (propensity score incidence cohort).
Baseline characteristics of statin users and nonusers were
compared using chi-square for categorical variables and
Student’s t test for continuous variables. Comparisons were
considered to be statistically signiﬁcant if the calculated
p value was 0.05. We used logistic regression to create
the propensity score and test the balance of covariates in
our models using the routines developed by Becker and
Ichino.19 We then used the routine by Leuven and Sianesi to
perform nearest number matching with a caliper of 0.001.20
For our secondary analysis, we used logistic regression
analysis to examine the odds ratios (OR) of outcome.
Potential confounders (as listed in Table 1) were introduced
as covariates in the models. Statistical analyses were per-
formed using STATA 12 (StataCorp, College Station,
Texas) and SPSS statistical software version 19 (IBM,
Armonk, New York).
Results
A total of 59,604 patients met inclusion criteria: 13,116
were excluded (2,124 burn or trauma patients, 516 who
received <90 days of statins, and 10,476 who received
statins after September 30, 2005). Of the remaining 46,488
patients, 13,640 were statin users and 32,848 were nonusers.
The mean  SD of cumulative duration of statin use among
statin users was 1,694  663 days. Table 1 depicts baseline
characteristics of this cohort.
We matched 6,956 pairs of statin users and nonusers using
propensity scores. The matched groups had similar baselinecharacteristics (Table 2). Among statin users, mean total
duration of statin use was 1,597 days; SD was 696 days
(median¼ 1,740 days, interquartiles¼ 1,097 and 2,160 days).
Approximately 26%of statinusers received themaximumdose
of their statin, deﬁned as 80 mg of simvastatin, 80 mg of pra-
vastatin, 80 mg of atorvastatin, and 40 mg of rosuvastatin.
Table 3 depicts the prevalence of selected ICD-9-CM codes.
In the sensitivity analysis, the propensity score incidence
cohort encompassed 6,798 statin users and 6,805 nonusers;
baseline characteristics of the 2 groups remained balanced
with no statistically signiﬁcant differences in any of the
matched variables.
Table 4 depicts the incidences and ORs of outcomes in
all of our analyses; ORs of CTD were lower among statin
users in all analyses.Discussion
Our study demonstrated that statin use is associated with
a lower risk of CTD. This ﬁnding was consistent in both
matched and unmatched cohorts.
Our results support other studies.3,4 In a case-control study,
313 patients with RA, who received statins or other lipid-
lowering agent, were matched to 1,252 controls.3 Subjects
were matched by patient age, sex, index date of RA diagnosis,
and number of years in the medical database. The adjusted OR
for developing RA in statin users was 0.59 (95% conﬁdence
interval [CI] ¼ 0.37 to 0.96). In another retrospective cohort
study, 55,919 persistent statin users (received a statin>80% of
the time)were comparedwith 57,690 nonpersistent statin users
(received a statin<20% of the time). Persistent statin users had
Miscellaneous/Statin and Connective Tissue Disease 887a lower risk of developing RA compared with nonpersistent
statin users (hazard ratio [HR]¼ 0.58; 95%CI¼ 0.52 to0.65).4
The TARA study (Trial of Atorvastatin in Rheumatoid
Arthritis) randomized 116 patients with RA to atorvastatin
or placebo and showed that atorvastatin use was associated
with an improvement in disease activity.21
Other studies concluded that statin use was not associated
with a difference in the risk ofCTD.5,6 One prospective cohort
study of 225,922 new statin users and 1,778,770 nonusers
found that, after adjusting for gender, co-morbidities, and
statin type, HR for the development of RA in new statin users
and nonusers was similar.5 In another population-based
cohort study (129,288 statin users to 600,241 nonusers),6 the
investigators created a propensity score, comprised of age,
gender, several co-morbidities, usage of several groups of
medications, socioeconomic status, and length of time
enrolled in their health care system. There was no association
between statin use and the development of RA (HR ¼ 0.93;
95% CI ¼ 0.73 to 1.18) or systemic lupus erythematosus
(HR¼ 1.08; 95%CI¼ 0.50 to 2.36); however, approximately
10% of the patients in the nonuser group started statins after
the initial evaluation.
More recently, a case-control study, including 508 RA
patients and 2,369 control subjects, found that statin use was
associated with an increased risk of developing RA.7 In this
study, each RA patient was matched to 5 control subjects
based on age, gender, and index date of RA diagnosis. After
adjustment for cardiovascular disease and other medica-
tions, the risk of RA was higher among statin users (adjusted
OR ¼ 1.71; 95% CI ¼ 1.16 to 2.53).
These conﬂicting results may be related to the limitations
of both randomized controlled studies and observational
studies; randomized controlled studies are not usually pow-
ered to detect uncommon adverse events, and observational
studies are potentially clouded by factors such as healthy-
user bias and the association of statin use with better health
care utilization.22 Observational studies often include
heterogeneous patient populations with differences in base-
line characteristics between treatment and control groups.
Statin users ultimately have higher disease burden necessi-
tating a statin prescription; hence, they may have a higher risk
of developing diseases that may be unrelated to statin
exposure. Furthermore, the presence of co-morbid conditions
increases health care utilization. Frequent evaluations by
a physician may result in more diagnoses and the possibility
of an ascertainment bias.23 However, statin users may be
more health conscious than nonusers. In a large prospective
cohort study, statin-adherent patients were less likely than
nonadherent patients to have motor vehicle accidents
and workplace accidents, after adjusting for potential
confounders.22 Additionally, statin use may act as a surrogate
marker for better access to care, because adherence to statin
therapy was associated with the use of preventive health
services.23
Propensity score matching helps to alleviate some of the
limitations of observational studies. We took into account
41 variables that would likely inﬂuence the prescription of
a statin. Notably, this study included a patient population that
has similar access to care and medications. In the military
health care system, patients are easily tracked because their
medical records are accessible at any military health carefacility. Medication distribution is recorded regardless of the
dispensing pharmacy and is available electronically. Because
of this, we were able to follow all eligible patients for the
duration of this study.
This study has some limitations. First, as with any retro-
spective observational study, some residual baseline con-
founders may still exist. Second, our study is solely dependent
on ICD-9-CM codes for conﬁrmation of diagnosis, which may
suffer from inaccuracy16,24; hence, we identiﬁed the presence
of CTD diagnosis by the presence of 3 separate ICD-9-CM
codes to improve its positive predictive value.16 Although not
ideal, we believe that any problems with this methodology in
terms of predictive value would affect both the statin users and
nonusers. Although we used ICD-9-CM codes identiﬁed
previously for CTD diagnoses,13 we did not perform an
external control of the actual presence of diseases, nor was our
study powered to identify which subgroup of diseases resulted
in the overall lower incidence of CTD among statin users. This
becomes particularly relevant in light of themarginal statistical
signiﬁcance of 0.05 in between groups. Finally, some data
suggest that different statins have different anti-inﬂammatory
effects23; however, we did not compare different statins in this
study because patientswere followed longitudinally for several
years, in which they used several statins and doses.
The anti-inﬂammatory properties of statins are postulated
to have beneﬁcial effects on cardiovascular diseases and
likely CTD.25,26 This study adds support that statins may
reduce the risk of CTD. A recent review by Lazzerini et al
demonstrated that inhibiting hydroxyl-methyl-glutaryl-
coenzyme A reductase alters downstream processes by
blocking cytokines and stimulating bone morphogenetic
proteins.26 Future research should focus on studying the
effects of statins in patients with high-risk features for CTD
development. This may include patients with positive serol-
ogies for rheumatoid factor and anticyclic citrullinated
peptide antibodies,27 or patients with familial history and the
shared epitope HLA-DRB1 who are at a higher risk for the
development of RA.28Disclosures
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